SOHO 2024 | Treatment-free remission after second-generation TKI treatment in CML
Massimo Breccia
• 4 Sep 2024
Massimo Breccia, MD, Sapienza University, Rome, Italy, discusses several trials exploring treatment-free remission and the disease-free interval (DFI) rate following chronic myeloid leukemia (CML) treatment with second-generation TKIs. Dr Breccia highlights factors that can predict treatment success but emphasizes the importance of discovering new clinical and prognostic factors to assess patient outcomes. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
